FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.
You may also be interested in...
FDA Drops Plans For Follow-On Biologics Policy
The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.
FDA Drops Plans For Follow-On Biologics Policy
The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.
Sandoz Sues FDA For Inaction On Omnitrope NDA
Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”